FDA clears tirzepatide as the first medicine for obstructive sleep apnea
The agency extended the Zepbound label to moderate-to-severe obstructive sleep apnea in adults with obesity, the first approval of any drug for the condition.
What's new
Zepbound (tirzepatide) is now approved for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and exercise.
Why it matters
Until now, treatment meant machines, mouth devices or surgery. A drug option changes who gets treated and how.
What's next
Insurers have to decide whether sleep apnea coverage applies when weight-loss coverage does not.
Regulators in the United States approved tirzepatide, sold for weight management as Zepbound, for adults who have obesity and moderate-to-severe obstructive sleep apnea. It is the first time any medicine has been cleared for the condition itself rather than for symptoms such as daytime sleepiness.
What the trials measured
The approval rests on two SURMOUNT-OSA trials. One enrolled people who were not using a breathing machine (CPAP), the other people who were. The main measure was the apnea-hypopnea index, the number of times per hour breathing stops or becomes shallow during sleep.
- People on tirzepatide had roughly 25 to 29 fewer events per hour after a year.
- People on placebo had about 5 fewer.
- A meaningful share of treated participants moved into the mild range or resolved entirely.
The peptide behind it
Tirzepatide is a single 39-amino-acid peptide that acts on two hormone receptors, GIP and GLP-1. It is injected once a week. The sleep benefit is thought to come mostly from weight loss, which reduces tissue around the airway, though the trials were not designed to separate the two.
What it does not change
The label does not replace CPAP for people who use it well, and it applies only to adults with obesity. Sleep specialists still need a sleep study to diagnose the condition. Common side effects remain the familiar ones for this drug class: nausea, diarrhoea, vomiting and constipation, mostly while the dose is being raised.
A drug option for a condition that used to be managed only with hardware is a shift for sleep clinics, but the diagnosis still starts in the sleep lab.
